Cardiac Rehabilitation Market To Reach USD 2.29 Billion By 2026 | Reports and Data
02 mars 2020 14h00 HE
|
Reports and Data
New York, March 02, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the cardiac rehabilitation market was valued at USD 1.37 billion in 2018 and is expected to reach...
Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee
10 nov. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
25 oct. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd
15 juin 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
13 avr. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
08 janv. 2015 16h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Non-Emergency Angioplasty Costs Higher in Hospitals Without Back-Up Surgery
04 nov. 2012 20h52 HE
|
American Heart Association
Study highlights:
Angioplasty costs for treating patients with stable symptoms are slightly higher in hospitals that do not have emergency heart surgery back-up, compared to those that do,...
Multiple Factors Influence Five-Year Survival After Angioplasty, Bypass Procedures
11 mai 2012 09h00 HE
|
American Heart Association
FRIDAY NEWS TIP
Embargoed for 9 a.m. ET
ATLANTA, May 11, 2012 (GLOBE NEWSWIRE) --The effectiveness of heart bypass grafts and angioplasty procedures on five-year survival varies significantly...
Two Anti-Clotting Regimens Similarly Effective in Patients Undergoing Angioplasty After Heart Attack
13 nov. 2011 08h00 HE
|
American Heart Association
Study Highlights:
Two anti-clotting treatments ― abciximab with heparin, or bivalirudin ― were similar in preventing death, subsequent heart attack or need for further...
Emergency Treatment for Heart Attack Improving but Delays Still Occur
19 sept. 2011 16h00 HE
|
American Heart Association
Study highlights:
Although improvements have been made in emergency heart attack treatment, delays still occur, particularly in transferring patients to hospitals that perform artery-opening...